Last reviewed · How we verify
Acute decompensated heart failure
Approved treatments
- Milrinone Lactate · Pfizer Inc.
Phosphodiesterase-3 inhibitor that increases cardiac contractility and promotes vasodilation through cAMP elevation.
Clinical guidelines
- FDA label — 1L
Milrinone Lactate Injection is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. - FDA label — 1L
Milrinone Lactate Injection is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Acute decompensated heart failure patent landscape — cliff calendar, originator estates, attackable patents
- Acute decompensated heart failure treatment landscape brief
- Acute decompensated heart failure treatment updates RSS
Frequently asked questions about Acute decompensated heart failure
What drugs treat Acute decompensated heart failure?
Tracked treatments include Milrinone Lactate.
What is the treatment for Acute decompensated heart failure?
Standard treatment for Acute decompensated heart failure includes Milrinone Lactate. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Acute decompensated heart failure?
FDA label publishes guidelines for Acute decompensated heart failure. 2 guideline references tracked.
Related
- Treatment landscape: Acute decompensated heart failure patent cliff · Acute decompensated heart failure CI report
- Treatment: Milrinone Lactate · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing